Related Experiment Video

Updated: Aug 8, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Opposing effects of endothelin-1 on C-type natriuretic peptide actions in rat cardiomyocytes

R Fixler1, Y Hasin, Y Eilam

  • 1Department of Cardiac Research Laboratory, Hadassah University Hospital, Jerusalem, Israel.

European Journal of Pharmacology
|July 13, 2001
PubMed

Insights

Endothelin-1 counteracts the effects of C-type natriuretic peptide (CNP) in cardiac myocytes. It inhibits CNP

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology

Background:

  • C-type natriuretic peptide (CNP) and Endothelin-1 are paracrine signaling molecules with opposing cardiovascular effects.
  • CNP elicits vasodilation and reduces cardiac myocyte contractility via cyclic guanosine monophosphate (cGMP).

Purpose of the Study:

  • To investigate the interaction between CNP and Endothelin-1 in cardiac myocytes.
  • To elucidate the mechanisms by which Endothelin-1 modulates CNP's effects.

Main Methods:

  • Experiments conducted on cardiac myocytes.
  • Measurement of myocyte contractility.
  • Quantification of intracellular cyclic guanosine monophosphate (cGMP) levels.

Main Results:

  • CNP reduced cardiac myocyte contractility and increased cGMP accumulation.
  • Endothelin-1 increased contractile amplitude.
  • Endothelin-1 abolished the negative inotropic effect of CNP.
  • Endothelin-1 reduced the negative inotropic effect of a membrane-permeable cGMP analog.
  • Endothelin-1 inhibited CNP-induced cGMP accumulation.

Conclusions:

  • Endothelin-1 antagonizes the negative inotropic actions of CNP in cardiac myocytes.
  • This antagonism is likely mediated by both reduced cGMP levels and inhibition of cGMP's negative inotropic effects.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies09:08

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Published on: May 24, 2021

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...